Re: Graphpad Prism 7 Trial
Sacha Weakland
A license will be issued within 3 business days if available. If no license is available, it may take more time before a license can be issued. The GraphPad Prism trial is good for 30 days so please plan accordingly.
Methods: This was a randomized, single-blind, multicenter trial conducted in three different clinical centers. Patients were randomly allocated into two groups in a ratio of 1:1. Intervention consisted of specific dietary and behavioral counseling. The primary outcome of this study was the rate of hemorrhoids at the time of discharge from the obstetrics unit. Categorical variables were compared by the Chi-Squared or Fisher exact tests, as appropriate. Continuous variables were compared using either the Student's t-test or the Mann-Whitney U test. Binary logistic regression model was used to identify independent predictors of hemorrhoids after delivery. This analysis was performed on factors with a p-value < 0.10 in univariate analysis. Statistical analysis was performed using IBM SPSS 23.0 and GraphPad Prism 9 software. A P-value of less than 0.05 was considered significant for all tests.
Before you buy a license, or if you need one immediately while you arrange payment: you can download a free 30-day trial of Prism from their website: This version has the full capabilities of Prism, so you can open and work on your saved Prism files.
Apart from the medical interventions aimed at mitigating symptomatologies, different therapeutic approaches are currently being explored, either by repurposing specific anti-viral agents, viz. remdesivir7, or by using corticosteroids to affect immunomodulation8, to treat patients progressing to severe disease. A number of patients also present with intravascular thrombosis and hence a role for prophylactic and therapeutic anticoagulation has also found a place in the standard of care in severe patients9. But in the absence of proven efficacy of any specific pathogen-targeted therapy, convalescent plasma (CP) transfusion is an age-old strategy for passive immunization, with the primary intention to supplement non-recovering patients with antibodies against specific pathogens10. Convalescent plasma therapy (CPT) has emerged as a widely tried strategy against COVID-19 too, having been explored in a large number of clinical trials all over the world11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37. Results of a multitude of randomized control clinical trials and efforts at meta-analysis revealed scarce evidence for significant clinical benefits of convalescent plasma therapy in COVID-1912,13,14,15,16,17,18,19,20,21,32, while others reported contradictory data22,23,24,25,26,27,33,34.
We report here insights gathered from a single-center open-label phase II randomized control trial done in Eastern India, on patients with severe COVID-19 disease with evidence for progressing to mild to moderate acute respiratory distress syndrome and identify the clinical and immunological benefits of CP transfusion. The trial was registered with the Clinical Trial Registry of India (No. CTRI/2020/05/025209). The primary outcomes were all-cause mortality on day 30 after enrolment and identification of immunological correlates of response to CPT, if any. The pre-specified secondary outcomes were time to recovery from ARDS, time taken to register negative RT-PCR and documenting any adverse effects on receiving CPT. In this study we find no significant clinical benefit in patients receiving CPT in terms of either survival benefit or reduction in the duration of hospital stay. While addressing the primary outcome of immunological correlates of convalescent plasma therapy we characterize a potential anti-inflammatory role of CP.
Another primary outcome of our trial had been identifying immune correlates of response to therapy, if any. Severe COVID-19 patients have been found by previous studies to experience a systemic hyper-inflammation characterized by a cytokine deluge. We have previously characterized the nature and dimension of this so-called cytokine storm in a fraction of these patients, comparing them to patients with mild COVID-19 disease39. On measuring plasma abundance of a panel of 48 cytokines in patients from both arms we found that correlative nature and magnitude of the individual components of the cytokine storm were not notably different at T1 in correlative network analysis (Fig. 4B, C). Data from a panel of 36 cytokines were included in all analyses, selected based on their measurable plasma abundance in at least 70% of the patients. The magnitude of plasma abundance was computed in comparison with the median abundance of individual cytokines in patients having mild COVID-19 disease reported as earlier39. Quite similar to this earlier study, a more significant attenuation of the systemic deluge of cytokines at T2 was noted in patients in the CPT arm, in terms of calming down the correlative upregulation (Fig. 4B, C). This was also evident from the reduction in the median abundance of major pathogenically significant cytokines as well as in terms of the number of patients in CPT arm registering such a change (Supplemental Fig. 3).
The secondary outcome of time taken for recovery from ARDS in all patients could not be determined accurately for all patients due to emergent operational limitations in access to computed tomography facility and arterial blood gas analysis for follow-up. Instead, recovery from COVID-19 disease was assessed in terms of time taken for discharge from the hospital, although it was not pre-specified in the trial protocol. Across all patients, we found no significant benefit in the CPT arm, either in terms of duration of hospital stay since the day of enrolment (Fig. 5A, median of 17 days for SOC vs 13 days for CPT arm, P-value of 0.098 on Mantel-Cox Log-rank test) or duration of hospital stay since admission (Fig. 5B, the median of 23 days for SOC vs 17 days for CPT arm, P-value of 0.0797 on Mantel-Cox Log-rank test). Disease course records for individual patients are given in Supplemental Table 4. Among the other secondary outcomes, a comparison of time taken for the patients in the two arms to register negative RT-PCR for SARS-CoV-2 could not be done due to statutory suspension of clinical use of repeat RT-PCR among hospitalized patients, which was to be the source of this data. Finally, no transfusion-related adverse effects were documented in any of the patients in the CPT arm.
The open-label randomized control trial for passive immunization of severe COVID-19 patients with CPT adds to the growing literature on similar trials of different designs and sample sizes. The present RCT was done in a low clinical resource setting in a single center. The clinical outcome comparisons did not reveal a significant relative benefit on receiving convalescent plasma therapy in severe COVID-19 patients, most of who had progressed to moderate acute respiratory syndrome.
A large number of clinical trials, both randomized control and matched-control ones, have been ongoing in different parts of the world since very early into the SARS-CoV-2 pandemic. They varied in study designs, sample sizes and scopes, more importantly even in the registered outcomes. A large trial in USA established the safety of this strategy of passive immunization11. But a number of RCTs reported no significant clinical benefit in the severe COVID-19 patients receiving convalescent plasma12,13,14,15,16,17,18,19,20,21. On the other hand, contradictory reports of some clinical benefits also have been there, both from matched-control studies22,23,24,25,26,27 as well as a few RCTs28,29,30,31. Different meta-analytic efforts also reported data showing both efficacy and inefficacy of CP in COVID-1932,33,34,35,36,37.
An important revelation of this trial has been the prominent anti-inflammatory effect of CPT, in terms of more prominent attenuation of the systemic surge of a large panel of cytokines compared to the standard care, perhaps due to CP proteome consisting of a number of anti-inflammatory proteins. The biology underlying the lack of response to convalescent plasma therapy in severe COVID-19 patients, despite this discernible anti-inflammatory effect, will be of great interest in subsequent mechanistic studies as well as in the context of therapeutic usage of specific monoclonal antibodies in COVID-19.
The major limitation of the present trial had been a small sample size, which also perhaps prevented the trial from discerning the relative clinical benefits. Moreover, the trial was open-label and the allocation of therapies was not concealed following randomization, which is another limitation of this trial. Altogether, this randomized control trial showed no relative clinical benefit in response to convalescent plasma therapy in severe COVID-19 patients as per the pre-specified primary outcome.
We express their gratitude to Abhijit Chowdhury and Anurag Agrawal for their valuable guidance while conceiving the trial and Mohd. Faruq for help with RT-PCR experiments. D.G. acknowledges funding for the RCT and associated immune monitoring studies from Council of Scientitific Industrial Research (CSIR), Govt. of India (MLP-129); R.P. acknowledges funding from CSIR (MLP-2005), Fondation Botnar (CLP-0031) and IUSSTF (CLP-0033).
As it turns out, getting another free trial could be as easy as removing a few files or changing your computer's MAC address. In this guide, I'll be showing you two methods, on both Mac and Windows, that you can use to test out software for as long as you need on your computer. And as a bonus, I'll show you that these techniques can be used to break the time-restraints on free, public Wi-Fi networks.
Some trial software store activation information in the form of files on your hard drive, which allows app installers to determine if that product had been previously installed on that same drive. This is why you're unable to reinstall trials over and over again.
aa06259810